Pittsburgh Seeks Breast Cancer Patients for Study on Coping

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

PITTSBURGH--The University of Pittsburgh Cancer Institute’s Division of Behavioral Medicine and Oncology is seeking young women with breast cancer for a research study on helping families cope with cancer.

The women will participate in educational and support groups for couples to discuss coping with a chronic illness, stress management skills, family communication, and parenting concerns. These groups, led by an oncology nurse and a health psychologist, will meet 1½ hours once a week for 8 weeks.

In addition, groups for children ages 3 to 12 may be available and would take place at the same time as the parent groups. The children will receive support and develop their skills for coping with feelings and managing stress.

To be eligible for this study, women must be premenopausal and have been diagnosed with breast cancer in the past 5 years, have a partner, and have children between the ages of 3 and 12. For more information, call 412-624-4806.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content